女性盐酸雷洛昔芬的临床效果。
文章的细节
-
引用
复制到剪贴板 -
Khovidhunkit W, Shoback DM
女性盐酸雷洛昔芬的临床效果。
安实习生地中海。1999年3月2;130 (5):431 - 9。
- PubMed ID
-
10068418 (在PubMed]
- 文摘
-
目的:评估盐酸雷洛昔芬的临床数据,选择性雌激素受体调节剂,最近被批准用于预防绝经后妇女的骨质疏松症。数据来源:从1980年到1998年5月发表英文文章被确定通过MEDLINE搜索。必威国际app参考书目、图书章节,会议摘要综述了更多相关的出版物。研究选择:出版物中包含的信息的发展背景,结构、作用机理、tissue-selective效果,包括盐酸雷洛昔芬的副作用。数据提取:数据在选定的文章进行了综述,及相关临床信息提取。数据综合:盐酸雷洛昔芬是为了找到一个治疗乳腺癌和骨质疏松症。它与雌激素受体结合显示tissue-selective效果;因此,它属于一个类的药物最近称为选择性雌激素受体调节剂。组织选择性雷洛昔芬可能通过几种机制:配体结构、配位体的相互作用与雌激素受体不同亚型在各组织和细胞内事件后配体绑定。雷洛昔芬estrogen-agonistic影响骨骼和脂质和estrogen-antagonistic对乳腺癌和子宫的影响。 An increase in bone mineral density at the spine, total hip, and total body has been reported with raloxifene but seems to be less than that seen with estrogen or alendronate therapy. Raloxifene has been shown to produce a reduction in total and low-density lipoprotein cholesterol concentrations similar to that produced by estrogen therapy, but high-density lipoprotein cholesterol and triglyceride concentrations do not increase during raloxifene therapy. In the uterus, raloxifene does not stimulate the endometrium. Long-term data on the effects of raloxifene in reduction of risk for fracture; prevention of cardiovascular events; cognitive function; and the incidence of breast, ovarian, and uterine cancer are not available. The most common adverse effect of raloxifene is hot flashes. CONCLUSIONS: Raloxifene has been shown to have beneficial effects in selected organs in postmenopausal women. Although estrogen remains the drug of choice for hormonal therapy in most postmenopausal women, raloxifene may be an alternative in certain groups of women at risk for osteoporosis.